Researchers at Concept to Medicine Biotech Co. Ltd., Lepu Biopharma Co. Ltd. and Shanghai Miracogen Inc. have described antibody-drug conjugates consisting of trophoblast glycoprotein (TPBG, 5T4)-targeting antibodies covalently linked to cytotoxic drugs through linkers reported to be useful for the treatment of cancer.
Scientists at Dongguk University and Korean Research Institute of Bioscience and Biotechnology have disclosed benzofuran compounds targeting heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1) acting as RAF proto-oncogene serine/threonine-protein kinase (RAF-1; c-Raf) inhibitors reported to be useful for the treatment of cancer.
Shanghai Apeiron Biotechnology Co. Ltd. has divulged kinesin-like protein KIF18A inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and Kartagener syndrome (primary ciliary dyskinesia).
Bisichem Co. Ltd. has disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, stroke, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer’s disease and Parkinson’s disease, among others.
SK Biopharmaceuticals Co. Ltd. has disclosed S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Ilab Co. Ltd. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer.
